High RBM3 expression was most frequently observed in mucinous carcinoma (88.2%), followed by clear cell carcinoma (71.9%), endometrioid carcinoma (69.0%), and serous carcinoma (34.3%). This evidence concerns the gene RBM3 and clear cell adenocarcinoma.